Institutional capital looks to unlock growth in Apac healthcare
Private market investments are accelerating drug discovery and capitalising on the burgeoning silver economy in the region.
Key Points
Institutional allocators across Asia Pacific (Apac) are increasingly tailoring their private market strategies to capture structural growth in healthcare, balancing the high-risk potential of drug discovery against the stable demand generated by demographic ageing.
Rather than viewing demographic shifts purely as a liability, sophisticated investors are leaning into venture capital, private equity and thematic strategies to fund life sciences, digital healthcare and drug manufacturing.